Biotechnology

Related Outside Content

Democratic presidential nominee, Hillary Clinton, put the spotlight on Mylan (NasdaqGS: MYL) EpiPen prices, triggering a selloff in biotech exchange traded funds and reminding investors of political risks in an election season. Biotech stocks were still reeling from Clinton’s Wednesday remarks, with the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) down 3.6% and SPDR S&P Biotech […]

Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in the sector. Biopharmaceutical giant Pfizer will pay Medivation shareholders $81.5 per share in cash, or a 21% markup to Medivation’s closing price on Friday of […]

The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have been in rally mode. That is prompting a spate of bullish calls on the once downtrodden group. Rare are the occasions […]

The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, is higher by 9% over the past month and that is just one sign that the once downtrodden biotechnology group is rebounding. As IBB and rival biotech ETFs have recently been gaining momentum, perhaps a sign that the group is putting election […]

The BioShares Biotechnology Products Fund (NasdaqGM: BBP) has capitalized on a string of acquisitions and outperformed other biotechnology- and pharmaceuticals-related exchange traded funds. BBP, which follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval, gained 4.0% over the past week and increased 9.1% over the past three […]

U.S. equities strengthened Wednesday with biotechnology stocks and sector-related exchange traded funds leading the charge on better-than-expected second quarter results. On Wednesday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index,rose 2.5%. The SPDR S&P Biotech ETF (NYSEArca: XBI), which follows a more equal weight methodology, gained 3.2% and was testing […]

As the equities market swings, traders have incorporated leveraged and inverse exchange traded funds to jump on short-term opportunities and hedge around events, like the Brexit vote. “If ever there was a market environment for uncertainty hedging, it is now,” Andy O’Rourke, Managing Director and Chief Marketing Officer at Direxion, told ETF Trends on a […]

After a seven year bull run and an increased uncertainty, people may expect the equities market will more likely pullback and give up some of its gains. Consequently, traders have turned to bearish or inverse exchange traded fund strategies to hedge against turns in a more volatile market. On an upcoming webcast this Wednesday, Sector Strategies […]

Biotechnology-related exchange traded funds are stuck in a malaise, with the underlying biotech sector declining for the ninth consecutive session, its longest selloff in a twenty years. Since June 6, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, declined 10.3%. Related: Hit The Lab With These 17 Biotech ETFs The […]

Janus Capital Group expanded its offerings to include four new exchange traded funds that track various health and living-related themes. Janus rolled out The Health and Fitness ETF (NasdaqGM: FITS), The Long-Term Care ETF (NasdaqGM: OLD), The Organics ETF (NasdaqGM: ORG) and The Obesity ETF (NasdaqGM: SLIM). Each fund comes with a 0.50% expense ratio. […]

Revitalizing the merger and acquisition outlook for biotech sector exchange traded funds, Pfizer (NYSE: PFE) announced it will buy biopharma company Anacor Pharmaceuticals (NasdaqGS: ANAC). Pfizer paid a 55% premium to Anacor’s closing price last Friday for $5.2 billion, gaining control over an experimental eczema treatment crisaborole, which posted strong results in Phase 3 clinical […]

While the health industry has underperformed so far this year, health care stocks and sector-related exchange traded funds can gain momentum on increased merger and acquisition activity. About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories (NYSE: ABT) agreeing to acquire St Jude Medical […]

Biotechnology stocks remain one of worst performing areas that are still stuck in a bear market after failing to recuperate earlier losses in the year, along with the broader market. However, exchange traded fund (ETF) investors still believe in a rebound. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, declined 17.0% […]

Expensive biologics have weighed on health care consumers. However, as the government tries to contain the soaring costs, a generic drugs-related exchange traded fund could capitalize on the growth of cheaper biosimilars. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which […]

The health care sector remains one of the worst performing areas of the market, despite the recovery off the Feb. 11 lows. With the earnings season coming up, health care stocks could be one of the few bright spots in the markets and exchange traded funds that track the sector could lead ahead. Based on […]

Pfizer (NasdaqGS: PFE) called off the deal with Allergan (NasdaqGS: AGN) on Wednesday, but there was a silver lining. Exchange traded funds that track the biotechnology sector surged as traders speculated that the two companies could court other merger targets. Biotechnology sector-related ETFs led gains on Wednesday. The BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), […]

As investors gear up for a volatile market in the year ahead, more aggressive exchange traded fund investors have utilized leveraged and inverse products to quickly adapt and capitalize on shifting market conditions. On the upcoming webcast, Tactical Strategies to Combat Market Volatility, Sylvia Jablonski, Managing Director and Co-Head of the Capital Markets & Institutional Strategy […]

Unloved ETF healthcare segment may provide a cheap opportunity for bargain hunters SPDR S&P 500 ETF (NYSEArca: SPY) is up 0.8% so far this year Investors may also be trying to catch a falling knife after the huge sell-off in the biotech sub-sector as biotechs remain in bear market territory Healthcare stocks, notably biotechnology names, […]

ETFs that implement derivative financial tools have drawn greater scrutiny from regulators Leveraged and inverse ETFs are being used as trading products over the short-term  Investors are taking both sides of the trade, or long bullish and short bearish positions during market turns Investors have utilized exchange traded funds that track leveraged and inverse strategies […]

Slow and steady value and conservative sectors are leading market gains RPV was best performing non-leveraged ETF across various Morningstar style categories  Close behind was RZV, which like RPV, targets companies exhibiting a value characteristic Since the start of the bull market, we may come to expect growth stocks like biotechnology and technology-sector exchange traded […]

U.S. regulators approved the sale of a lower-priced copy of an expensive blockbuster biologic drug, paving the way for further biosimilars to hit the market and supporting the outlook for the relatively new generic drugs exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global […]

The $3.5 billion First Trust Dorsey Wright Focus 5 ETF (NasdaqGM: FV) has helped exchange traded fund investors target some high-flying sectors, but the momentum strategy recently cut its biotech position for a defensive play. The First Trust Dorsey Wright Focus 5 ETF follows DWA’s relative strength ranking system where sector ETFs are compared to […]

While the broad U.S. equities market strengthened Thursday, the biotechnology sector looked under the weather, with sector-related exchange traded funds slipping to 52-week lows. On Thursday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) fell 3.6% and SPDR S&P Biotech ETF (NYSEArca: XBI) dropped 3.5%. Year-to-date, IBB declined 19.2% and XBI decreased 26.4%. Both biotech ETFs […]

Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of its treatment for depressive disorder did not meet primary endpoints, Reuters reports. KMI shares plunged 42.3% Thursday, […]

We are heading into the earnings season, and investors are growing concerned over the outlook for biotechnology stocks and sector-related exchange traded funds as bellwether Celgene Corp. (NasdaqGS: CELG) expects weaker-than-expected growth last year. Biotech stocks were among the worst performers Monday, with the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and […]

After a stellar October, the equities market and stock exchange traded funds had a more tepid November, with traders waiting for a potential rate hike in December. Over November, the Dow Jones Industrial Average was down 0.6%, the Nasdaq Composite was 0.4% lower and the S&P 500 dipped 1.1%. The best performing non-leveraged ETFs over […]

Another acquisition deal in the biotechnology space for a rare disease specialist is fueling a jump in biotech stocks and sector-related exchange traded funds as traders hope further consolidation will help the industry maintain its momentum. Dublin-based Shire Plc (NasdaqGS: SHPG) has acquired U.S.-based Dyax Corp (NasdaqGM: DYAX) for about $5.9 billion, or potentially up […]

Investors interested in positioning their portfolios ahead of changes to major market trends may target specific market segments with sector-specific exchange traded funds. For instance, on the recent webcast, How Well Do Your Know Your Sectors?, David Mazza, V.P. and Head of Research at State Street Global Advisor, pointed out that the utilities sector was […]

U.S. prosecutors subpoenaed Valeant Pharmaceuticals International (NYSE: VRX), reinvigorating the drug pricing drama. However, the broader pharmaceutical space and sector-related exchange traded fund were shaking off the renewed pricing scrutiny Thursday as the industry rebounded along with the markets. The U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office sought information […]

With the advancements in biotechnology generating some attractive investment opportunities, exchange traded fund investors may now focus on a group of companies that specialize in the growing field of cancer immunotheraphy. The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR) began trading Wednesday, October 14, according to a press release. CNCR has a 0.79% expense ratio. “Immunotherapy […]